An expanded access program (EAP) allows doctors to give medicine to seriously ill patients before it is approved by local regulatory agencies.
The goal of this Expanded Access Protocol is to provide access to mifomelatide for eligible cachectic adult patients with advanced, unresectable pancreatic ductal adenocarcinoma (PDAC) who lack satisfactory therapeutic alternatives for their cancer cachexia and are not eligible for current mifomelatide clinical trials.
A participant may receive mifomelatide under this EAP if:
* A licensed doctor submits a request,
* The participant is eligible
* The country allows the EAP
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-02; most recent amendment 2026-02-16.
Status change: Available → No Longer Available2026-02-16